
Annual report 2025
added 03-26-2026
Inhibikase Therapeutics Net Debt 2011-2026 | IKT
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Inhibikase Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -8.64 M | -6.84 M | - | -13.9 K | 355 K | -146 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 355 K | -8.64 M | -3.06 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Celldex Therapeutics
CLDX
|
-26.5 M | $ 34.83 | 2.85 % | $ 2.31 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 4.3 | 8.31 % | $ 10.3 B | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 5.98 | 16.72 % | $ 403 B | ||
|
Aligos Therapeutics
ALGS
|
-132 M | $ 6.69 | -12.73 % | $ 66.1 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 307.49 | -3.95 % | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 22.72 | 4.17 % | $ 1.06 B | ||
|
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 103.65 | 1.5 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.09 | 0.32 % | $ 5.09 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
BioXcel Therapeutics
BTAI
|
56.3 M | $ 1.17 | 9.67 % | $ 14.3 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-133 M | $ 1.41 | 5.19 % | $ 363 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.33 | 1.69 % | $ 463 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.54 | 1.43 % | $ 3.12 B | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 4.89 | 4.71 % | $ 792 M | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Cabaletta Bio
CABA
|
-76.6 M | $ 3.33 | -5.4 % | $ 335 M | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.67 | 3.5 % | $ 444 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-163 M | - | - | $ 546 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Cidara Therapeutics
CDTX
|
-188 M | - | - | $ 1.41 B | ||
|
Citius Pharmaceuticals
CTXR
|
-2.99 M | $ 0.87 | 1.44 % | $ 5.85 M | ||
|
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B |